ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,746.35
      0.02%
      US Tech 100
      19,518.40
      -0.31%
      Dow Jones
      42,540.28
      0.87%
      Brent Oil
      71.455
      0.71%
      Bitcoin
      66,031.71
      1.30%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. UK
      5. LSE
      6. Okyo Pharma Limited (OKYO)

      7. Okyo Pharma Limited (OKYO) News

      OKYO

      Okyo Pharma (OKYO)

      Okyo Pharma Limited
      		Date:
      Sort by:
       Showing the most relevant articles for your search:LSE:OKYO
      DateTimeSourceHeadlineSymbolCompany
      09/10/20247:00AMUK RegulatoryOKYO Pharma Announces Chairman Acquires SharesLSE:OKYOOkyo Pharma Limited
      09/05/20247:00AMUK RegulatoryOKYO Pharma Announces Chairman Acquires SharesLSE:OKYOOkyo Pharma Limited
      08/27/20247:00AMUK RegulatoryOKYO Pharma Granted U.S. Patent Covering OK-101’s Potential for Treating Symptoms of Dry Eye DiseaseLSE:OKYOOkyo Pharma Limited
      08/23/20249:00AMUK RegulatoryOKYO Pharma CEO Interview to Air on Bloomberg TVLSE:OKYOOkyo Pharma Limited
      08/23/20247:00AMUK RegulatoryOKYO Pharma Announces Chairman Acquires SharesLSE:OKYOOkyo Pharma Limited
      08/21/20247:00AMUK RegulatoryOKYO Pharma Announces Chairman Acquires SharesLSE:OKYOOkyo Pharma Limited
      08/15/202412:13PMUK RegulatoryOKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual ConferenceLSE:OKYOOkyo Pharma Limited
      08/06/20247:00AMUK RegulatoryOKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of UseLSE:OKYOOkyo Pharma Limited
      07/11/20247:00AMUK RegulatoryOKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101LSE:OKYOOkyo Pharma Limited
      07/10/20247:00AMUK RegulatoryOKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye DiseaseLSE:OKYOOkyo Pharma Limited
      05/08/20247:00AMUK RegulatoryOKYO Pharma Announces Participation in May 2024 Investor ConferencesLSE:OKYOOkyo Pharma Limited
      04/30/20247:00AMUK RegulatoryOKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)LSE:OKYOOkyo Pharma Limited
      04/08/20247:00PMUK RegulatoryOKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024LSE:OKYOOkyo Pharma Limited
      04/02/20247:00AMUK RegulatoryOKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive SurgeryLSE:OKYOOkyo Pharma Limited
      03/22/20247:00AMUK RegulatoryOKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101LSE:OKYOOkyo Pharma Limited
      03/21/20247:00AMUK RegulatoryOKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease TrialLSE:OKYOOkyo Pharma Limited
      03/20/20247:00AMUK RegulatoryOKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader EventLSE:OKYOOkyo Pharma Limited
      02/09/20247:36AMInvestorsHub NewsWireOKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal PainLSE:OKYOOkyo Pharma Limited
      02/09/20247:00AMUK RegulatoryOKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal PainLSE:OKYOOkyo Pharma Limited
      01/31/20247:00AMUK RegulatoryOKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory BoardLSE:OKYOOkyo Pharma Limited
      05/22/20233:15AMUK RegulatoryOKYO Pharma Limited London Stock Exchange DelistingLSE:OKYOOkyo Pharma Limited
      05/22/20233:00AMUK RegulatoryLondon Stock Exchange Notice Cancellation - OKYO PHARMA LIMITEDLSE:OKYOOkyo Pharma Limited
      05/19/20236:22AMAlliance NewsAlliance NewsIN BRIEF: Okyo Pharma to move shares to New York with London delistingLSE:OKYOOkyo Pharma Limited
      05/19/20233:00AMRNS Non-RegulatoryOKYO Pharma Limited ADS Program collapseLSE:OKYOOkyo Pharma Limited
      05/15/20232:00AMUK RegulatoryOKYO Pharma Limited Change of Record Time and Last Day of DealingsLSE:OKYOOkyo Pharma Limited
      05/11/20239:27AMAlliance NewsAlliance NewsIN BRIEF: Okyo Pharma delays delisting from London trading to May 22LSE:OKYOOkyo Pharma Limited
      05/11/20237:00AMRNS Non-RegulatoryOKYO Pharma Limited Webull Corporate Communications Service PlatformLSE:OKYOOkyo Pharma Limited
      05/11/20232:00AMUK RegulatoryOKYO Pharma Limited Change of Delisting Date to 22 May 2023LSE:OKYOOkyo Pharma Limited
      05/03/20238:00AMUK RegulatoryOKYO Pharma Limited Result of MeetingLSE:OKYOOkyo Pharma Limited
      05/03/20232:00AMRNS Non-RegulatoryOKYO Pharma Limited Presentation on OK-101 at ASCRSLSE:OKYOOkyo Pharma Limited
       Showing the most relevant articles for your search:LSE:OKYO

      Your Recent History

      LSE
      51IM
      Qnb Fin 23
      Delayed Upgrade Clock